Procedural Advantages of a Novel Drug-Eluting Coronary Stent With Ultra-Thin Struts and Bioabsorbable Abluminal Polymer Coating in an All-Comers Registry
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 814
- 主要终点
- In-hospital major cardiac adverse events
研究概览
简要总结
This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CAD for PCI, consecutive patients
排除标准
- •Age under 18
- •Bare Metal Stents or Scaffolds
研究组 & 干预措施
Common DES
Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
干预措施: Currently common drug-eluting stent (DES) (Device)
Synergy Stent
Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
干预措施: Synergy Stent (Device)
结局指标
主要结局
In-hospital major cardiac adverse events
时间窗: One week post-procedure
In-hospital major cardiac adverse events were collected up to one week after procedure throughout the in-patients stay
次要结局
未报告次要终点
研究者
Haitham Abu Sharar
Principal Investigator
University Hospital Heidelberg